Litcius/Paper detail

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

Steven M. Rowe, Jonathan B. Zuckerman, Daniel Dorgan, Jorge Lascano, Karen McCoy, Manu Jain, Michael S. Schechter, Sherstin T. Lommatzsch, V. Indihar, Noah Lechtzin, Kimberly McBennett, Caroline Callison, Cynthia D. Brown, Theodore G. Liou, Kelvin D. MacDonald, Samya Z. Nasr, Susan Bodie, M. Vaughn, Eric B. Meltzer, Ann Barbier

2023Journal of Cystic Fibrosis138 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboCohortAdverse effectCystic fibrosisDosingInternal medicineRandomized controlled trialPlacebo-controlled studyGastroenterologyAnesthesiaDouble blindPathologyAlternative medicineCystic Fibrosis Research AdvancesRNA Interference and Gene DeliveryInhalation and Respiratory Drug Delivery
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study | Litcius